Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience

Background Combination of dabrafenib–trametinib is one of the standard treatments in patients with BRAF-mutated advanced malignant melanoma (MM). Real-world data on the usage of this combination is scarce, especially from India. Here, we are reporting our early experience with the usage of this comb...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sandip Ganguly, Joydeep Ghosh, Deepak Mishra, Gautam Biswas, Deepak Dabkara, Somanth Roy, Bivas Biswas
Formato:	article
Lenguaje:	EN
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2021
Materias:	malignant melanoma braf mutation dabrafenib trametinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ca8a8c87174249fa9e9b1eb06129f6e3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ca8a8c87174249fa9e9b1eb06129f6e3
record_format	dspace
spelling	oai:doaj.org-article:ca8a8c87174249fa9e9b1eb06129f6e32021-11-25T01:50:29ZEarly Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience2278-330X2278-430610.1055/s-0041-1736032https://doaj.org/article/ca8a8c87174249fa9e9b1eb06129f6e32021-11-01T00:00:00Zhttp://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1736032https://doaj.org/toc/2278-330Xhttps://doaj.org/toc/2278-4306Background Combination of dabrafenib–trametinib is one of the standard treatments in patients with BRAF-mutated advanced malignant melanoma (MM). Real-world data on the usage of this combination is scarce, especially from India. Here, we are reporting our early experience with the usage of this combination therapy. Materials and Methods This is a single institutional data assessment of patients with BRAF-mutated MM registered and treated with BRAF–MEK inhibitors in our hospital. Clinico-pathological features and treatment details were reviewed for all patients. Results A total of seven patients with BRAF-mutated MM treated with this combination therapy with a median age of 66.5 years (range: 49–72 years) and a male:female ratio of 3:4. Six (85.7%) patients had metastatic disease at presentation. In total, 80% of our patient population had two or less than two sites of metastasis at presentation. The initial response rate of the study population was 71%. The drug was well tolerated with fever being the most common side effect which was seen in two (28.5%) of the patients. Conclusion Combination of dabrafenib–trametinib is effective in patients with BRAF-mutated MM with good tolerability. Further studies are required to look for improvement in outcome in this group of patients.Sandip GangulyJoydeep GhoshDeepak MishraGautam BiswasDeepak DabkaraSomanth RoyBivas BiswasThieme Medical and Scientific Publishers Pvt. Ltd.articlemalignant melanomabraf mutationdabrafenibtrametinibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENSouth Asian Journal of Cancer (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	malignant melanoma braf mutation dabrafenib trametinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	malignant melanoma braf mutation dabrafenib trametinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Sandip Ganguly Joydeep Ghosh Deepak Mishra Gautam Biswas Deepak Dabkara Somanth Roy Bivas Biswas Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
description	Background Combination of dabrafenib–trametinib is one of the standard treatments in patients with BRAF-mutated advanced malignant melanoma (MM). Real-world data on the usage of this combination is scarce, especially from India. Here, we are reporting our early experience with the usage of this combination therapy. Materials and Methods This is a single institutional data assessment of patients with BRAF-mutated MM registered and treated with BRAF–MEK inhibitors in our hospital. Clinico-pathological features and treatment details were reviewed for all patients. Results A total of seven patients with BRAF-mutated MM treated with this combination therapy with a median age of 66.5 years (range: 49–72 years) and a male:female ratio of 3:4. Six (85.7%) patients had metastatic disease at presentation. In total, 80% of our patient population had two or less than two sites of metastasis at presentation. The initial response rate of the study population was 71%. The drug was well tolerated with fever being the most common side effect which was seen in two (28.5%) of the patients. Conclusion Combination of dabrafenib–trametinib is effective in patients with BRAF-mutated MM with good tolerability. Further studies are required to look for improvement in outcome in this group of patients.
format	article
author	Sandip Ganguly Joydeep Ghosh Deepak Mishra Gautam Biswas Deepak Dabkara Somanth Roy Bivas Biswas
author_facet	Sandip Ganguly Joydeep Ghosh Deepak Mishra Gautam Biswas Deepak Dabkara Somanth Roy Bivas Biswas
author_sort	Sandip Ganguly
title	Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
title_short	Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
title_full	Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
title_fullStr	Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
title_full_unstemmed	Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
title_sort	early experience with dabrafenib–trametinib combination in patients with braf-mutated malignant melanoma—a single-center experience
publisher	Thieme Medical and Scientific Publishers Pvt. Ltd.
publishDate	2021
url	https://doaj.org/article/ca8a8c87174249fa9e9b1eb06129f6e3
work_keys_str_mv	AT sandipganguly earlyexperiencewithdabrafenibtrametinibcombinationinpatientswithbrafmutatedmalignantmelanomaasinglecenterexperience AT joydeepghosh earlyexperiencewithdabrafenibtrametinibcombinationinpatientswithbrafmutatedmalignantmelanomaasinglecenterexperience AT deepakmishra earlyexperiencewithdabrafenibtrametinibcombinationinpatientswithbrafmutatedmalignantmelanomaasinglecenterexperience AT gautambiswas earlyexperiencewithdabrafenibtrametinibcombinationinpatientswithbrafmutatedmalignantmelanomaasinglecenterexperience AT deepakdabkara earlyexperiencewithdabrafenibtrametinibcombinationinpatientswithbrafmutatedmalignantmelanomaasinglecenterexperience AT somanthroy earlyexperiencewithdabrafenibtrametinibcombinationinpatientswithbrafmutatedmalignantmelanomaasinglecenterexperience AT bivasbiswas earlyexperiencewithdabrafenibtrametinibcombinationinpatientswithbrafmutatedmalignantmelanomaasinglecenterexperience
_version_	1718414721018757120

Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience

Ejemplares similares